HIV血清質(zhì)控盤(pán)（Qualification Panels）

廣州健侖生物科技有限公司

SeraCare Life Sciences公司主要在美國(guó)、歐洲和亞洲提供促進(jìn)人類(lèi)和動(dòng)物診斷和治療學(xué)的探索,、開(kāi)發(fā)和生產(chǎn)的產(chǎn)品和服務(wù),。其業(yè)務(wù)分為兩個(gè)部分：診斷和生物制藥產(chǎn)品和生物服務(wù)。診斷和生物制藥產(chǎn)品部門(mén)生產(chǎn)和銷(xiāo)售診斷和控制面板產(chǎn)品,，用于測(cè)試傳染性疾病的臨床實(shí)驗(yàn)室及員工培訓(xùn)和能力測(cè)試,。生物服務(wù)部門(mén)提供生物銀行、來(lái)樣加工和測(cè)試服務(wù),。

美國(guó)SeraCare收購(gòu)BBI公司,，即原BBI血清盤(pán)已經(jīng)改名為SeraCare血清盤(pán)。

其產(chǎn)品包括有：傳染病陽(yáng)性質(zhì)控品,、疾病標(biāo)準(zhǔn)品,、細(xì)菌陽(yáng)性質(zhì)控品,、人血清白蛋白、人伽馬球蛋白,、牛血清白蛋白,、血清盤(pán)、人血漿,、人血清,。

SeraCare的血清盤(pán)包括：HIV-1轉(zhuǎn)化盤(pán)、HIV性能盤(pán),、HBV轉(zhuǎn)化盤(pán),、HBV性能盤(pán)、HCV轉(zhuǎn)化盤(pán),、HCV性能盤(pán),、弓形蟲(chóng)性能盤(pán)、線(xiàn)性盤(pán)和質(zhì)控盤(pán)等等,。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱,、瘧疾、流感,、A鏈球菌,、合胞病毒、腮病毒,、乙腦,、寨卡、黃熱病,、基孔肯雅熱,、克錐蟲(chóng)病、違禁品濫用,、肺炎球菌,、軍團(tuán)菌、化妝品檢測(cè),、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清,、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品,。

歡迎咨詢(xún)

歡迎咨詢(xún)2042552662

美國(guó)Seracare HIV血清質(zhì)控盤(pán)（Qualification Panels）

美國(guó)Seracare

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱(chēng)】 廣州健侖生物科技有限公司

【市 場(chǎng) 部】    楊永漢

【】 

【騰訊Q Q】 2042552662

【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

線(xiàn)粒體是人類(lèi)細(xì)胞將糖轉(zhuǎn)化成能量的重要工廠(chǎng),。西奈山伊坎醫(yī)學(xué)院的科學(xué)家們開(kāi)發(fā)了一種新測(cè)序技術(shù)，可以幫助人們理解線(xiàn)粒體基因?qū)€(gè)體患病風(fēng)險(xiǎn)的影響,，比如糖尿病,、心臟病和癌癥。這項(xiàng)研究發(fā)表在近期的Nucleic Acids Research雜志上,。
在年齡,、體重和壞習(xí)慣(比如吸煙)相同的人中,，有些會(huì)生病有些卻不會(huì)。研究者們一直對(duì)這一點(diǎn)感到迷惑,，并嘗試通過(guò)飲食和核基因來(lái)確定個(gè)體的患病風(fēng)險(xiǎn),。但這樣的分析遺漏了線(xiàn)粒體基因(mtDNA)的差異，mtDNA遺傳自我們的母親,，每個(gè)細(xì)胞都有這樣的DNA。
近年來(lái)研究表明,，線(xiàn)粒體發(fā)生錯(cuò)誤會(huì)引起嚴(yán)重的疾病,。然而由于mtDNA的異質(zhì)性很大，分析mtDNA變異對(duì)個(gè)體疾病風(fēng)險(xiǎn)的影響非常復(fù)雜,。
這項(xiàng)研究展示了*可以準(zhǔn)確鑒定mtDNA異質(zhì)性的測(cè)序技術(shù),，Mseek。細(xì)胞里的mtDNA含量很少,，過(guò)去這方面一直沒(méi)有什么進(jìn)展,。人們意識(shí)到了mtDNA的異質(zhì)性，但卻無(wú)法再單細(xì)胞水平上建立決定性的理論,。
“研究者們一直在尋找能夠準(zhǔn)確測(cè)序mtDNA的低成本方法,，”西奈山伊坎醫(yī)學(xué)院的助理教授Ravi Sachidanandam博士說(shuō)。“現(xiàn)在我們做到了這一點(diǎn),。Mseek可以鑒定線(xiàn)粒體中的功能紊亂,，使mtDNA成為了有用的生物學(xué)指標(biāo)。此外,，人們還可以將mtDNA作為潛在的靶標(biāo),，治療癌癥和多種遺傳疾病。”
據(jù)Dr. Sachidanandam介紹,，新測(cè)序技術(shù)達(dá)到了*的靈敏性,、特異性和測(cè)序深度，能夠得到高純度的mtDNA,，檢測(cè)不同版本的mtDNA或mtDNA變體,。
Mseek主要是利用酶清除細(xì)胞核DNA，只留下線(xiàn)粒體DNA進(jìn)行測(cè)序,。研究人員將Mseek用于多個(gè)細(xì)胞系,，鑒定了不同細(xì)胞樣本中的mtDNA“指紋”。他們還通過(guò)追蹤mtDNA變體發(fā)現(xiàn),，mtDNA異質(zhì)性在單細(xì)胞水平上是穩(wěn)定維持的,。

Mitochondria are important plants where human cells convert sugar into energy. Scientists at the Icahn School of Medicine in Mount Sinai have developed a new sequencing technology that can help people understand the impact of mitochondrial genes on individual risk factors such as diabetes, heart disease and cancer. This study was published in the recent issue of Nucleic Acids Research.
Some people who are the same in age, weight, and bad habits (such as smoking) are sick but not others. Researchers have always been puzzled by this and tried to determine the risk of the individual through diet and nuclear genes. But such an analysis missed the difference in mitochondrial genes (mtDNA) that we inherited from our mother, and each cell has such DNA.
Recent studies have shown that mistakes in mitochondria can cause serious diseases. However, due to the heterogeneity of mtDNA, it is very complicated to analyze the impact of mtDNA mutation on individual disease risk.
This study shows the first sequencing technology that can accuray identify mtDNA heterogeneity, Mseek. The mtDNA content in the cells is very small, and there has been little progress in this area. People are aware of the heterogeneity of mtDNA but can no longer establish deterministic theories at the single cell level.
“Investigators are always looking for low-cost methods that can accuray sequence mtDNA,” said Dr. Ravi Sachidanandam, an assistant professor at Icahn Medical School in Mount Sinai. "Now we have done this. Mseek can identify functional disorders in mitochondria, making mtDNA a useful biological indicator. In addition, people can use mtDNA as a potential target for the treatment of cancer and many genetic diseases."
According to Dr. Sachidanandam, the new sequencing technology has achieved unprecedented sensitivity, specificity, and sequencing depth, enabling high-purity mtDNA to detect different versions of mtDNA or mtDNA variants.
Mseek uses enzymes to remove nuclear DNA, leaving only mitochondrial DNA for sequencing. The researchers used Mseek for multiple cell lines and identified mtDNA "fingerprints" in different cell samples. They also found that by tracking mtDNA variants, mtDNA heterogeneity was stable at the single cell level.